OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bradley on Exercise in Treatment-Related AE Management

November 16th 2018

Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the importance of exercise in the management of prostate cancer treatment-related adverse events.

Rationale for Pembrolizumab Plus mFOLFOX6 in Advanced CRC

November 15th 2018

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses the rationale behind the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer.

Dr. Markman Discusses the Future of Treatment for Ovarian Cancer

November 15th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care® for Gynecological Cancers, discusses the future of treatment for patients with ovarian cancer.

Dr. Weber on Duration of Checkpoint Inhibitor Therapy in Melanoma

November 15th 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses duration of checkpoint inhibitor therapy in patients with melanoma.

Dr. O'Brien on CAR T Cells in CLL

November 15th 2018

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses the potential for CAR T-cell therapy for the treatment of chronic lymphocytic leukemia.

Dr. Kohman on the NELSON Trial of Lung Cancer Screening

November 15th 2018

Leslie J. Kohman, MD, FACS, Distinguished Service Professor of Surgery, Upstate Medical University, Upstate Cancer Center, discusses the results of the NELSON trial of screening in lung cancer.

Dr. Drilon on Tepotinib and Gefitinib in MET+ EGFR-Mutant NSCLC

November 15th 2018

Alexander E. Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of tepotinib and gefitinib (Iressa) in patients with MET-positive EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Brahmer on the Benefit of Immunotherapy in Metastatic NSCLC

November 15th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the benefit of immunotherapy in the treatment of patients with metastatic non–small cell lung cancer (NSCLC).

Dr. Iqbal on HER2-Driven Gastric Cancer

November 15th 2018

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the treatment of patients with HER2-driven gastric cancer.

Dr. McDermott on an Analysis of the CheckMate-214 Study in RCC

November 14th 2018

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses an analysis of the CheckMate-214 study in advanced renal cell carcinoma (RCC).

Dr. Andreadis Discusses the Role of Ibrutinib in DLBCL

November 14th 2018

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with diffuse large B-cell lymphoma.

Dr. Parker on the Rationale for Radiotherapy in Metastatic Prostate Cancer

November 14th 2018

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the rationale for radiotherapy in the treatment of newly-diagnosed metastatic prostate cancer.

Dr. Nguyen on Treatment Approaches for Patients With Advanced Ovarian Cancer

November 14th 2018

Trung Nguyen, DO, MBA, clinical assistant professor, Obstetrics and Gynecology, Gynecologic Oncology, Stanford Medicine, discusses treatment approaches for patients with advanced ovarian cancer.

Dr. Feldman on the Future of Durvalumab and Tremilimumab in NSCLC

November 14th 2018

Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses the future of durvalumab (Imfinzi) and tremelimumab in non–small cell lung cancer (NSCLC).

Dr. Rugo on Resistance to CDK4/6 Inhibitors in HR+ Breast Cancer

November 14th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses resistance to CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.

Dr. Lassen Discusses TRK Fusions in Pediatric Patients

November 14th 2018

Ulrik Lassen, MD, PhD, head of the Phase I Unit at Rigshospitalet, discusses TRK fusions in pediatric patients with cancer.

Dr. Powles on Biomarkers for Immunotherapy in Bladder Cancer

November 14th 2018

Thomas Powles MBBS, MRCP, MD, professor of Genitourinary Oncology, lead, Solid Tumour Research, Barts Cancer Institute, director, Barts Cancer Centre, discusses biomarkers for immunotherapy in bladder cancer.

Dr. Gorantla on the Impact of the APHINITY Trial in HER2+ Breast Cancer

November 14th 2018

Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, discusses the impact of the APHINITY trial on the treatment of patients with HER2-positive breast cancer.

Dr. Choueiri on Biomarkers in RCC

November 14th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses biomarkers in renal cell carcinoma.

Dr. Pegram on Future Impact of Biosimilars in Oncology

November 13th 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the future impact of biosimilars in oncology.